Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Hose

Showing results (51-60 of 189) with videos related to

Pageof 19
Sort By:
Oncotarget|May 10, 2014
A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategyAlboukadel Kassambara, Claire Gourzones-Dmitriev, Surinder Sahota, et al.
International Journal of Molecular Sciences|April 12, 2022
Resemblance-Ranking Peptide Library to Screen for Binders to Antibodies on a Peptidomic ScaleFelix Jenne, Sergey Biniaminov, Nathalie Biniaminov, et al.
Haematologica|March 26, 2017
Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysisMartin Granzow, Ute Hegenbart, Katrin Hinderhofer, et al.
Oncotarget|December 13, 2017
<i>CD24</i>, <i>CD27</i>, <i>CD36</i> and <i>CD302</i> gene expression for outcome prediction in patients with multiple myelomaElina Alaterre, Sebastien Raimbault, Hartmut Goldschmidt, et al.
Cytometry. Part B, Clinical Cytometry|November 13, 2018
BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myelomaGuilhem Requirand, Nicolas Robert, Stéphanie Boireau, et al.
BMC Cancer|May 15, 2010
Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarraysKarène Mahtouk, Jérôme Moreaux, Dirk Hose, et al.
Cancer|April 28, 2011
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasoneUlrike Klein, Anna Jauch, Thomas Hielscher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myelomaMaximilian Merz, Judith Ritsch, Christina Kunz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Association of antigen-specific T-cell responses with antigen expression and immunoparalysis in multiple myelomaSabrina Fichtner, Dirk Hose, Melanie Engelhardt, et al.
Hematological Oncology|March 16, 2013
Sorafenib in patients with refractory or recurrent multiple myelomaAnna Yordanova, Dirk Hose, Kai Neben, et al.
Pageof 19

Showing results (51-60 of 189) with videos related to

Sort By:
Pageof 19
Oncotarget|May 10, 2014
A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategyAlboukadel Kassambara, Claire Gourzones-Dmitriev, Surinder Sahota, et al.
International Journal of Molecular Sciences|April 12, 2022
Resemblance-Ranking Peptide Library to Screen for Binders to Antibodies on a Peptidomic ScaleFelix Jenne, Sergey Biniaminov, Nathalie Biniaminov, et al.
Haematologica|March 26, 2017
Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysisMartin Granzow, Ute Hegenbart, Katrin Hinderhofer, et al.
Oncotarget|December 13, 2017
<i>CD24</i>, <i>CD27</i>, <i>CD36</i> and <i>CD302</i> gene expression for outcome prediction in patients with multiple myelomaElina Alaterre, Sebastien Raimbault, Hartmut Goldschmidt, et al.
Cytometry. Part B, Clinical Cytometry|November 13, 2018
BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myelomaGuilhem Requirand, Nicolas Robert, Stéphanie Boireau, et al.
BMC Cancer|May 15, 2010
Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarraysKarène Mahtouk, Jérôme Moreaux, Dirk Hose, et al.
Cancer|April 28, 2011
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasoneUlrike Klein, Anna Jauch, Thomas Hielscher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myelomaMaximilian Merz, Judith Ritsch, Christina Kunz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Association of antigen-specific T-cell responses with antigen expression and immunoparalysis in multiple myelomaSabrina Fichtner, Dirk Hose, Melanie Engelhardt, et al.
Hematological Oncology|March 16, 2013
Sorafenib in patients with refractory or recurrent multiple myelomaAnna Yordanova, Dirk Hose, Kai Neben, et al.
Pageof 19